Lynx Investment Advisory Gilead Sciences, Inc. Call Options Transaction History
Lynx Investment Advisory
- $139 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GILD
# of Institutions
1,913Shares Held
1.02BCall Options Held
12MPut Options Held
9.03M-
Black Rock Inc. New York, NY121MShares$11.6 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$11.1 Billion0.15% of portfolio
-
Capital World Investors Los Angeles, CA76.2MShares$7.36 Billion0.88% of portfolio
-
Capital Research Global Investors Los Angeles, CA60.4MShares$5.84 Billion0.94% of portfolio
-
State Street Corp Boston, MA59.3MShares$5.73 Billion0.18% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $121B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...